This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Brainstorms

Antipsychotic Polypharmacy: Squandering Precious Resources?

Stephen M. Stahl

Published: February 1, 2002

Article Abstract

Atypical antipsychotics represent a major advance in psychopharmacology, based on compelling evidence that monotherapy with atypical antipsychotics has superior benefits over monotherapy with conventional antipsychotics. Despite becoming the most expensive drugs in psychiatry and for many health care systems, atypical antipsychotics have now largely replaced conventional antipsychotics due to the perceived greater efficacy of the atypicals. An especially expensive clinical utilization of these already expensive drugs is to combine them with another antipsychotic (polypharmacy) in an attempt to further enhance their efficacy.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...